AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma
Shots:
- The BORA P-III trial involves assessing of Fasenra (benralizumab) enrolling patients in ratio (1:1) who have completed one of the two SIROCCO or CALIMA P-III trials- administering Fasenra 30 mg SC q4w or q8w
- BORA results (N= 1926): improvement in efficacy outcomes; overall annual asthma exacerbation rate (eosinophil counts of 300 cells per μL) is consistent; 74% of patients with (eosinophil counts ≥300 cells per μL) resulted in exacerbation free
- AstraZeneca’s Fasenra is a first respiratory biologic- approved in the US- EU including Japan and other countries as an add-on treatment in severe eosinophilic Asthma. It is available as FD SC injection with a prefilled syringe administered q4w for the first three doses followed by q8w
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com